Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience

PURPOSE: Pegvisomant (PEG) efficaciously controls IGF-I excess in acromegaly and possesses a positive impact on glucose metabolism. Data on very prolonged PEG treatment are still limited, therefore, we investigated the effects of 10-years PEG on disease control, maximal tumour diameter (MTD), and me...

Descripción completa

Detalles Bibliográficos
Autores principales: Pirchio, R., Auriemma, R. S., Montini, M. E., Vergura, A., Pivonello, R., Colao, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105681/
https://www.ncbi.nlm.nih.gov/pubmed/36892739
http://dx.doi.org/10.1007/s40618-022-01980-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105681/
https://www.ncbi.nlm.nih.gov/pubmed/36892739
http://dx.doi.org/10.1007/s40618-022-01980-7

Ejemplares similares